[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![razbag1 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::322114402.png) zakachop [@razbag1](/creator/twitter/razbag1) on x XX followers
Created: 2025-07-28 20:05:30 UTC

$mira
qwe
MIRA Pharmaceuticals (NASDAQ: MIRA) 8-K Summary — July 28, 2025

MIRA Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for Ketamir-2, an oral NMDA receptor antagonist aimed at treating neuropathic pain. This enables MIRA to begin U.S. clinical trials, with a Phase 2a study planned for Q4 2025. Preclinical data showed Ketamir-2 outperformed gabapentin and pregabalin without ketamine-like side effects.

MIRA is completing the single ascending dose (SAD) portion of its Phase X trial and will start the multiple ascending dose (MAD) phase next. Additionally, MIRA is progressing on the acquisition of SKNY Pharmaceuticals and advancing MIRA-55, a cannabinoid analog comparable to morphine in pain models.


XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1949924195699163639/c:line.svg)

**Related Topics**
[nasdaq](/topic/nasdaq)
[mira](/topic/mira)
[$mira](/topic/$mira)
[coins cardano](/topic/coins-cardano)
[coins gaming](/topic/coins-gaming)

[Post Link](https://x.com/razbag1/status/1949924195699163639)